[1] World Health Organization. Global tuberculosis report 2018. https://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?ua=1[2018-11-18]
[2] Tiberi S, Sotgiu G, D'Ambrosio L, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J, 2016; 47, 1235-43. doi:  10.1183/13993003.02146-2015
[3] Tremblay LW, Fan F, Blanchard JS. Biochemical and structural characterization of Mycobacterium tuberculosis β-Lactamase (BlaC) with the carbapenems Ertapenem and Doripenem. Biochemistry, 2010; 49, 3766-73. doi:  10.1021/bi100232q
[4] Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry, 2007; 46, 11998-2004. doi:  10.1021/bi701506h
[5] Kumar P, Arora K, Lloyd JR, et al. Meropenem inhibits D, D-carboxypeptidase activity in Mycobacterium tuberculosis. Molecular Microbiology, 2012; 86, 367-81. doi:  10.1111/j.1365-2958.2012.08199.x
[6] Lavollay M, Arthur M, Fourgeaud M, et al. The Peptidoglycan of Stationary-Phase Mycobacterium tuberculosis Predominantly Contains Cross-Links Generated by L, D-Transpeptidation. J Bacteriol, 2008; 190, 4360-6. doi:  10.1128/JB.00239-08
[7] Payen MC, Wit WC, Martin C, et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. International J Tuberculosis Lung Disease, 2012; 16, 558-60. doi:  10.5588/ijtld.11.0414
[8] De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem/clavunate added to linezolid containing regimens in the treatment of MDR/XDR-TB. Eur Respir J, 2013; 41, 1386-92. doi:  10.1183/09031936.00124312
[9] Zhang D, Wang Y, Lu J, et al. In vitro activity of β-lactams in combination with β-lactams inhibitors against multidrug-resistant Mycobacterium tuberculosis isolates. AAC, 2015; 60, 393-9. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=c49de4fae597a324029ccd3f617a8d04
[10] Kaushik A, Ammerman NC, Tasneen R, et al. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother, 2017; 72, 2320-5. doi:  10.1093/jac/dkx152
[11] Collins L, Franzblau SG. Microplate Amamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. AAC, 1997; 41, 1004-9. doi:  10.1128/AAC.41.5.1004
[12] Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected Gram-negative organisms. AAC, 2003; 47, 1902-6. doi:  10.1128/AAC.47.6.1902-1906.2003
[13] Reddy VM, Einck L, Andries K, et al. In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207. AAC, 2010; 54, 2840-6. doi:  10.1128/AAC.01601-09
[14] Rey-Jurado E, Tudó G, de la Bellacasa JP, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents, 2013; 41, 278-80. doi:  10.1016/j.ijantimicag.2012.11.011
[15] S Majumdar, SK Basu. Killing of intracellular Mycobacterium tuberculosis by receptor-mediated drug delivery. AAC, 1991; 35, 135-40. doi:  10.1128/AAC.35.1.135
[16] Yamada K, Yamamoto Y, Yanagihara K, et al. In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa. J Infect Chemother, 2012; 18, 472-8. doi:  10.1007/s10156-011-0359-2
[17] Veziris N, Truffot C, Mainardi JL, et al. Activity of carbapenems combined with clavulanate against murine tuberculosis. AAC, 2011; 55, 2597-600. doi:  10.1128/AAC.01824-10
[18] Lee J, Carroll MW, Choi H, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med, 2012; 367, 1508-18. doi:  10.1056/NEJMoa1201964
[19] Zareifopoulos N, Panayiotakopoulos G. Neuropsychiatric Effects of Antimicrobial Agents. Clin Drug Investig, 2017; 37, 423-7. doi:  10.1007/s40261-017-0498-z
[20] Nakashima M, Uematsu T, Ueno K, et al. phase I study of L-627, biapenem, a new parenteral carbapenem antibiotic. Int J Clin Pharmacol Ther Toxicol, 1993; 31, 70-6. http://cn.bing.com/academic/profile?id=5bc7eeb7315aa7ff965d950199b42668&encoded=0&v=paper_preview&mkt=zh-cn
[21] Abate G, Hoffner SE. Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime. Diagn Microbiol Infect Dis, 1997; 28, 119-22. doi:  10.1016/S0732-8893(97)00012-6
[22] England K, Boshoff HI, Arora K, et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. AAC, 2012; 56, 3384-7. doi:  10.1128/AAC.05690-11